Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

NIH Grants & Funding for Lymphoid Neoplasm | Kisho | Kisho

Back to Lymphoid Neoplasm

Lymphoid Neoplasm — NIH Grants & Funding

Active and recent NIH-funded research on Lymphoid Neoplasm. Data from NIH RePORTER, last 36 months.

MONDO:0005157

NIH-funded research on Lymphoid Neoplasm

active grants

institutions

researchers

new in last 12 mo.

$73.4M in NIH funding over the last 36 months. Data from NIH RePORTER.

I'm looking for:

Or filter by research focus

Only show active grants

Basic Science(26)

Basic ScienceZIACompleted

Molecular diagnosis and outcome prediction in lymphoma

Staudt, Louis·DIVISION OF BASIC SCIENCES - NCI

$1,577,900 (FY2025)

Lymphoid Neoplasm — NIH Grants & Funding

Basic Science(26)

Molecular diagnosis and outcome prediction in lymphoma

Functional genomic screens for molecular targets in cancer

Oncogenic mechanisms and molecular targets in lymphoma

Role of BCL10 somatic mutations in lymphomagenesis and response to BCR-targeted therapies

New control of oncogene activation in T-cell leukemia

Cooperative role of TET2 and IDH2 mutations in angioimmunoblastic T-cell lymphomagenesis

The role of ATM in the suppression of lymphoid malignancy

Role of CREBBP missense mutations in lymphomagenesis

Investigating and modeling MYD88L265P and co-occurring mutations in mature B-cell malignancies

The Role of Pacs1-Wdr37 inLymphocyte Quiescence and Survival

Translational(12)

Therapeutic Strategies and Molecular Correlates in Aggressive B-cell Lymphomas

Targeting GSK3B in refractory B-cell malignancies

Analysis and Therapeutic Targeting of the Linear-Ubiquitination Pathway in Hodgkin Lymphoma

Investigating the IL-1R Pathway in Anaplastic Large Cell Lymphoma for Targeted Therapy

Modeling Marginal Zone Lymphomagenesis

MALT1 as a rational therapeutic target in African American ancestry patients with DLBCL

Understanding the pathogenesis of classic Hodgkin lymphoma in persons living with HIV through conventional and spatial transcriptomics

Molecular Diagnosis, Prognosis, and Therapeutic Targets in Lymphoma

Understanding and manipulating programmed cell death (PCD) pathways to facilitate lymphoid tumor killing by CAR T cells

Targeted Therapies for Lymphoid Malignancies

Clinical(10)

Clinical development of mechanism-based lymphoma therapies

Understanding and Targeting Aberrant RNA Splicing in Leukemia

Efforts to Discover Novel Therapies and Reduce Treatment Toxicities for Lymphoma and Chronic Lymphocytic Leukemia Patients Through Collaboration and the NCTN

Targeted treatment of B-cell Lymphoma

Targeting Tumor-Associated Macrophages to Treat Lymphoma

Exploring CD38 molecular biology and imaging in multiple myeloma pathogenesis

Paradigm Shift in the Management of Patients with Previously Untreated Chronic Lymphocytic Leukemia through NCI-sponsored Clinical Trials

Expedited Expansion Cohort Clinical Trial for Relapsed/Refractory 'no-option' Non-Hodgkin's Lymphoma/Leukemia Patients

Mechanisms of treatment failure in chimeric antigen receptor T cell therapy

Understanding the in vivo impact of immunotherapies in splenic lymphoma by intravital three-photon microscopy

Epi / Nat. History(2)

Decoding Mosaic Chromosomal Alterations in Lymphoid Malignancy Risk and Outcomes

Elucidating novel epigenetic modifications implicated in multiple myeloma risk disparities

Gene/Cell Therapy(3)

Novel CAR T cell engineering strategies for effective eradication of solid and liquid tumors

Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies

Defining the Mechanism and Function of DNA Double Strand Break Induced Inhibition of V(D)J Recombination

Biomarker / Dx(1)

Genetic and Epigenetic Biomarkers for B-cell Lymphoma

Other(3)

Lymphoma Disease Discovery and Definition

New mechanisms for modulating the MALT1 oncoprotein

Re-designing anti-CD20 monoclonal antibody therapy using novel insights into limitations of innate immune cytotoxicity